Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …

Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors,
chronic kidney disease, and the cardiovascular system and has profound impacts on …

Background Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no
approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta …

Background Metabolic dysfunction–associated steatohepatitis (MASH) is a progressive liver
disease associated with liver-related complications and death. The efficacy and safety of …

Background Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1)
receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for
steatotic liver disease associated with metabolic syndrome. MASLD is the most common …

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic
liver disease globally and is currently estimated to affect up to 38% of the global adult …

The AIDS epidemic has been a global public health issue for more than 40 years and has
resulted in~ 40 million deaths. AIDS is caused by the retrovirus, HIV-1, which is transmitted …

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most
common chronic liver disease globally, affecting more than a third of the world's adult …

A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors
such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led …